Novo-backed Windward Bio targets up to $1B valuation in US IPO

Novo-backed Windward Bio Group AG said on November 9, 2026 it is targeting a valuation of up to $1 billion in its US IPO, seeking up to $185.3 million by selling roughly 10.3 million shares at $16.

Detected & updated continuously · Source: Nebula